Munich, Planegg (Germany), February 9th, 2026 – leon-nanodrugs GmbH (“LEON”), specializing in the development and commercialization of scalable nanoparticle manufacturing technologies, today announced the appointment of Dr. Blerina Shkodra as Chief Scientific Officer (CSO) and Dr. Matthias Schumacher as Chief Technology Officer (CTO).
The appointments strengthen LEON’s scientific and technological leadership as the company advances from technology development to global deployment of its scalable, GMP-compatible manufacturing platform for advanced therapeutics.
As Chief Scientific Officer, Dr. Shkodra will lead LEON’s scientific strategy, building on several years in senior scientific leadership roles within the company. Her focus will include formulation science and application development across emerging therapeutic modalities, including RNA-based therapeutics, cancer vaccines, and cell and gene therapies. She brings deep expertise in nanoparticle formulation and translational development, supporting LEON’s mission to enable rapid, reproducible encapsulation processes across diverse payloads and indications.
In his role as Chief Technology Officer, Dr. Schumacher will oversee the continued expansion of LEON’s technology and equipment portfolio. Having spent several years leading the development of LEON’s FR-JET® platform, he brings both scientific and engineering expertise to the leadership team. As CTO, he will drive the next phase of innovation, focusing on the integration of LEON’s technology into global biopharma R&D and supply chains for advanced therapeutics and RNA-based medicines.
Together, Dr. Shkodra and Dr. Schumacher bring a complementary combination of formulation science and advanced engineering expertise to the leadership team, supporting LEON’s efforts to address critical manufacturing bottlenecks in advanced therapeutics.
“These appointments mark an important step as LEON moves into full commercial deployment,” said Dr. Wolfgang Hofmann, Chief Executive Officer at LEON. “Strengthening our scientific and technological leadership supports our long-term vision of enabling flexible and scalable nanoparticle manufacturing.”
LEON’s platform addresses accelerating global demand for scalable, flexible, and high-performance, fit-for-purpose nanoparticle manufacturing, particularly as the field moves toward more individualized therapies. With its strengthened leadership structure, the company is accelerating product development and commercial execution to support partners worldwide.
